Extrapolating our findings from ALCL into a more general context, we hypothesize that multi-layered combinatorial treatments targeting the PDGFRβ-STAT5 signaling axis via imatinib upstream and AC-4-130 downstream might bolster response rates. Here, PDGFRB is linked to anaplastic large cell lymphoma.